Elevated level of serum human epididymis protein 4 (HE4) predicts disease severity and mortality in COVID-19 pneumonia

被引:0
|
作者
Suto, Renata [1 ,2 ,3 ]
Pocsi, Marianna [1 ]
Szabo, Zsolt [3 ]
Fejes, Zsolt [1 ]
Ivady, Gergely [1 ]
Kerekes, Gyoergy [4 ]
Fagyas, Miklos [5 ]
Nagy, Attila [6 ]
Szentkereszty, Zoltan [3 ]
Kappelmayer, Janos [1 ]
Nagy Jr, Bela [1 ]
机构
[1] Univ Debrecen, Fac Med, Dept Lab Med, Debrecen, Hungary
[2] Univ Debrecen, Fac Med, Doctoral Sch Kalman Laki, Debrecen, Hungary
[3] Univ Debrecen, Fac Med, Intens Care Unit, Gyula Kenezy Campus, Debrecen, Hungary
[4] Univ Debrecen, Fac Med, Dept Internal Med, Intens Care Unit, Debrecen, Hungary
[5] Univ Debrecen, Fac Med, Dept Cardiol, Div Clin Physiol, Debrecen, Hungary
[6] Univ Debrecen, Fac Publ Hlth, Dept Prevent Med, Debrecen, Hungary
关键词
SARS-CoV-2; Inflammation; COVID-19; Disease; Pneumonia; Biomarker; HE4; Outcome; RESPIRATORY-DISTRESS-SYNDROME; CRITICALLY-ILL; TUMOR-MARKER; HOMOLOGY; SEPSIS;
D O I
10.1186/s12890-023-02811-y
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background We retrospectively analyzed serum level of human epididymis protein 4 (HE4) as a pulmonary inflammatory biomarker in patients with COVID-19 pneumonia in association with disease severity and outcome.Methods Ninety-nine (40 critically ill, 40 severe and 19 mild) COVID-19 patients and as controls 25 age- and sex-matched non-COVID-19 bacterial sepsis subjects were included. Serum HE4 was measured by an immunoassay (Architect (R) i1000SR, Abbott) in the baseline samples of all study participants obtained at intensive care unit (ICU) admission or during outpatient clinic visit and follow-up sera were available in case of 30 COVID-19 subjects with life-threating conditions. Associations were studied between serum HE4, routinely available laboratory parameters, clinical characteristics, and disease progression.Results Baseline HE4 level was significantly higher (P < 0.0001) in critically ill (524.7 [300.1-1153.0] pmol/L) than severe COVID-19 subjects (157.4 [85.2-336.9] pmol/L) and in mild SARS-CoV-2 infection (46.7 [39.1-57.2] pmol/L). Similarly increased HE4 concentrations were found in bacterial sepsis (1118.0 [418.3-1953.0] pmol/L, P = 0.056) compared to critically ill COVID-19 individuals. Serum HE4 levels significantly correlated with age, SOFA-score, inflammation-dependent biomarkers, and the degree of lung manifestation evaluated by chest CT examination in ICU COVID-19 individuals. Based on ROC-AUC curve analysis, baseline HE4 independently indicated the severity of COVID-19 with an AUC value of 0.816 (95% CI [0.723-0.908]; P < 0.0001), while binary logistic regression test found HE4 as an independent prognostic parameter for death (OR: 10.618 [2.331-48.354]; P = 0.002). Furthermore, COVID-19 non-survivors showed much higher baseline HE4 levels without a substantial change under treatment vs. survivors (P < 0.0001). Finally, pre-treatment HE4 level of >= 331.7 pmol/L effectively predicted a larger risk for mortality (Log-Rank P < 0.0001) due to severe COVID-19 pneumonia.Conclusion Elevated serum HE4 level at ICU admission highly correlates with COVID-19 severity and predicts disease outcome.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Elevated level of serum human epididymis protein 4 (HE4) predicts disease severity and mortality in COVID-19 pneumonia
    Renáta Sütő
    Marianna Pócsi
    Zsolt Szabó
    Zsolt Fejes
    Gergely Ivády
    György Kerekes
    Miklós Fagyas
    Attila Nagy
    Zoltán Szentkereszty
    János Kappelmayer
    Béla Nagy
    BMC Pulmonary Medicine, 23
  • [2] The Utility of Serum Human Epididymis Protein 4 (HE4) in Patients With a Pelvic Mass
    Montagnana, Martina
    Lippi, Giuseppe
    Ruzzenente, Orazio
    Bresciani, Valentina
    Danese, Elisa
    Scevarolli, Silvia
    Salvagno, Gian Luca
    Giudici, Silvia
    Franchi, Massimo
    Guidi, Gian Cesare
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2009, 23 (05) : 331 - 335
  • [3] Human epididymis secretory protein 4 in serum (HE4) as a marker of ovarian cancer
    Qu, K. Z.
    Li, H.
    Whitmire, R.
    Sferruzza, A.
    Bender, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer
    Nagy, Bela, Jr.
    Bhattoa, Harjit Pal
    Steiber, Zoltan
    Csoban, Maria
    Szilasi, Maria
    Mehes, Gabor
    Mueller, Monika
    Lazar, Jozsef
    Kappelmayer, Janos
    Antal-Szalmas, Peter
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2014, 52 (11) : 1639 - 1648
  • [5] Serum human epididymis protein 4 (HE4) levels in colorectal cancer patients.
    Kemal, Yasemin
    Gonullu, Guzin
    Bedir, Addulkerim
    Tomak, Leman
    Derebey, Murat
    Erdem, Dilek
    Gor, Ufuk
    Yucel, Idris
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] A clinical study of serum human epididymis protein 4 (HE4) in the diagnosis of pancreatic cancer
    Liu, Weiqi
    Liu, Weiling
    Lin, Keng
    Liu, Yuhua
    Hu, He
    Yang, Lina
    INDIAN JOURNAL OF CANCER, 2022, 59 (02) : 223 - 229
  • [7] Human Epididymis Protein 4 (HE4) as a Serum Tumor Biomarker in Patients With Ovarian Carcinoma
    Chang, Xiaohong
    Ye, Xue
    Dong, Li
    Cheng, Hongyan
    Cheng, Yexia
    Zhu, Lirong
    Liao, Qinping
    Zhao, Yang
    Tian, Li
    Fu, Tianyun
    Chen, Jun
    Cui, Heng
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2011, 21 (05) : 852 - 858
  • [8] Human epididymis protein 4 (HE4): a potential biomarker for IPF
    Jo, Sung
    Winkler, Julia
    Sullivan, Andrew
    Luus, Lia
    Herzog, Erica
    Ray, Adrian
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [9] Highly elevated human epididymis protein 4 (HE4) following endometrioma rupture: a case report
    Sukur, Yavuz Emre
    Taskin, Salih
    Simsir, Coskun
    Atabekoglu, Cem
    Sonmezer, Murat
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2018, 38 (06) : 885 - 886
  • [10] Biochemical and functional characteristics of human epididymis protein 4 (HE4)
    Schiumarini, Domitilla
    Ferraro, Simona
    Panteghini, Mauro
    BIOCHIMICA CLINICA, 2014, 38 (05) : 368 - 373